bit.bio wins Biotech Company of the Year at the Cambridge Independent Science andTechnology awards.
bit.bio wins Biotech Company of the Year at the Cambridge Independent Science andTechnology awards.
bit.bio wins Biotech Company of the Year at the Cambridge Independent Science andTechnology awards.
bit.bio wins Biotech Company of the Year at the Cambridge Independent Science andTechnology awards.
SynbioBeta CEO John Cumbers talks reimagining cell therapies through cell reprogramming with Rick Klausner and bit.bio CEO.
Dr Farah Patell-Socha, VP of Research Products discusses the launch of ioSkeletal Myocytes.
IBI Journal Q&A with Dr Mark Kotter who talks about producing every human cell type at scale.
bit.bio and the London Institute of Mathematical Sciences (LIMS) want to recreate every human cell type.
bit.bio receives £40m of backing for technology that it claims can reliably reprogram stem cells.
Mark Kotter Bit Bio ideaSpace, focus on a founder, celebrating 10 years of idea space.
The investors behind Bit Bio's series A fundraise.
Bit Bio raises series A funding for its programming approach to human cells.